Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics

Novo Holdings, the holding company comprising Novo Nordisk and managing the Novo Nordisk Foundation’s assets, has made a new investment through its seed capital arm.

The incubator Novo Seeds is funding a company called Hemab ApS, which is focused on developing bispecific antibodies for rare bleeding disorders. Co-founded by two former Novo Nordisk execs in their hemophilia R&D department, Hemab is aiming for hemophilia to be its first target with related blood diseases to follow afterward.